Key facts
- It has raised $33.9M; the latest was Later Stage VC ($29.9M) in Oct 2024.
- Notable investors include BDC Capital, Investissement Quebec, Fonds de solidarite FTQ, Accel-Rx, Centre for Commercialization of Regenerative Medicine — 8 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 8 names
- ·Watchlist + deal alerts for KisoJi Biotechnology
- ·The full record, as it builds
Funding rounds
No funding rounds for KisoJi Biotechnology are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About KisoJi Biotechnology
Developer of multi-specific antibodies intended to address targets in oncology and other diseases. The company's services include developing antibody discoveries that are designed to significantly improve the outcome of cancer and other therapeutic indications, enabling doctors to treat cancer and generate antibodies.
- Sector
- Healthcare
- HQ
- Montreal, Canada
- Founded
- 2009
- Website
- kisojibiotech.com/
- Ownership
- Privately Held (backing)
KisoJi Biotechnology doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in KisoJi Biotechnology shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on KisoJi Biotechnology in its N-PORT filings yet. We sweep new filings monthly.